E. Brendel
- Hepatology top 5%
- Oncology top 5%
- Colorectal Cancer Treatments and Studies 11
- Cancer Treatment and Pharmacology 11
- Drug Transport and Resistance Mechanisms 10
- Pharmaceutical Science top 2%
- Cancer Research top 5%
-
- Lung Cancer Treatments and Mutations 6
-
- Analytical Methods in Pharmaceuticals 8
-
- Diabetes Treatment and Management 8
-
- Melanoma and MAPK Pathways 7
-
- Pharmacology and Obesity Treatment 5
- Co-authors
- Dirk StrumbergBrian SchwartzAhmad AwadaHeike RichlyRalf A. HilgerR. VoigtmannM. E. ScheulenS. Seeber
- Journals
- European Journal of Cancer (5 papers)European Journal of Clinical Pharmacology (5 papers)Journal of Clinical Oncology (4 papers)
- Partner nations
- GermanyUnited StatesSwitzerland
In The Last Decade
E. Brendel
53 papers receiving 2.1k citations
Hit Papers
Peers
Comparison fields: 5 of 102
- Hepatology 289
- Oncology 818
- Pharmaceutical Science 146
- Cancer Research 310
- Pulmonary and Respiratory Medicine 558
Countries citing papers authored by E. Brendel
This map shows the geographic impact of E. Brendel's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Brendel with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Brendel more than expected).
Fields of papers citing papers by E. Brendel
This network shows the impact of papers produced by E. Brendel. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Brendel. The network helps show where E. Brendel may publish in the future.
Co-authorship network
The 25 scholars most cited alongside E. Brendel, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | 2011 | 10 | |
| 2 | 2011 | 16 | |
| 3 | 2010 | 16 | |
| 4 | 2008 | 22 | |
| 5 | 2008 | 68 | |
| 6 | 2007 | 4 | |
| 7 | 2006 | 24 | |
| 8 | 2006 | 87 | |
| 9 | 2005 | 99 | |
| 10 | A phase I study of BAY 43-9006, a novel Raf kinase and VEGFR inhibitor, in combination with taxotere in patients with advanced, solid tumors | 2004 | 4 |
| 11 | 2004 | 35 | |
| 12 | 2004 | 44 | |
| 13 | 2003 | 19 | |
| 14 | 2002 | 38 | |
| 15 | 2002 | 47 | |
| 16 | 1998 | 23 | |
| 17 | 1996 | 53 | |
| 18 | 1990 | 38 | |
| 19 | 1989 | 3 | |
| 20 | 1988 | 9 |
About E. Brendel
E. Brendel is a scholar working on Oncology, Analytical Chemistry, Pharmacology, Endocrinology, Diabetes and Metabolism and Pharmacology, having authored 53 papers that have together received 2.1k indexed citations. Recurring topics across this work include Colorectal Cancer Treatments and Studies (11 papers), Cancer Treatment and Pharmacology (11 papers), Drug Transport and Resistance Mechanisms (10 papers), Analytical Methods in Pharmaceuticals (8 papers), Diabetes Treatment and Management (8 papers), Melanoma and MAPK Pathways (7 papers), Lung Cancer Treatments and Mutations (6 papers) and Pharmacology and Obesity Treatment (5 papers). The work is most often cited by research in Hepatology (289 citations), Oncology (818 citations), Pharmaceutical Science (146 citations), Cancer Research (310 citations) and Pulmonary and Respiratory Medicine (558 citations). E. Brendel has collaborated with scholars based in Germany, United States and Switzerland. Frequent co-authors include Dirk Strumberg, Brian Schwartz, Ahmad Awada, Heike Richly, Ralf A. Hilger, R. Voigtmann, M. E. Scheulen, S. Seeber, D. Voliotis and N. Schleucher. Their work appears in journals such as European Journal of Cancer, European Journal of Clinical Pharmacology, Journal of Clinical Oncology, Annals of Oncology and Cancer Chemotherapy and Pharmacology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.